George Song Portfolio
Invests via Superstring Capital Management LP | Managed by George Song
Invests via Superstring Capital Management LP
Managed by George Song
Automatically Tracked
George Song Profile
A seasoned entrepreneur and investor, George Song has made a significant mark in the technology startup landscape. With a career focused on innovative business solutions, he brings deep operational expertise and visionary leadership to emerging companies. His background includes founding successful ventures that leverage cutting-edge technologies, driving substantial growth and market expansion. George’s role as an active investor enables him to nurture budding talent while fostering collaboration across various sectors. With his comprehensive understanding of entrepreneurial dynamics and capital markets, he is well-positioned to identify lucrative opportunities within fast-evolving industries.
A seasoned entrepreneur and investor, George Song has made a significant mark in the technology startup landscape. With a career focused on innovative business solutions, he brings deep operational expertise and visionary leadership to emerging companies. His background includes founding successful ventures that leverage cutting-edge technologies, driving substantial growth and market expansion. George’s role as an active investor enables him to nurture budding talent while fostering collaboration across various sectors. With his comprehensive understanding of entrepreneurial dynamics and capital markets, he is well-positioned to identify lucrative opportunities within fast-evolving industries.
Investment Philosophy & Strategy
In a rapidly evolving technology landscape, investment opportunities are abundant for visionary leaders. George Song is well-versed in identifying and cultivating the next wave of innovative startups. His unique approach combines operational know-how with an entrepreneurial mindset, enabling a keen assessment of business models that demonstrate scalability. By fostering synergistic partnerships within the ecosystem, he aims to amplify growth trajectories while optimizing resource allocation. With an emphasis on sectors at the forefront of disruption, his strategy prioritizes agility and market responsiveness as pivotal components for sustainable success.
In a rapidly evolving technology landscape, investment opportunities are abundant for visionary leaders. George Song is well-versed in identifying and cultivating the next wave of innovative startups. His unique approach combines operational know-how with an entrepreneurial mindset, enabling a keen assessment of business models that demonstrate scalability. By fostering synergistic partnerships within the ecosystem, he aims to amplify growth trajectories while optimizing resource allocation. With an emphasis on sectors at the forefront of disruption, his strategy prioritizes agility and market responsiveness as pivotal components for sustainable success.
Disclaimer: This Portfolio is derived from and computed based on publicly available data from SEC filings.
Gain and growth charts are calculated per selected timeframe:
71.75%
Gain -1.15%
Monthly
1.67%
Yearly
22.04%
Drawdown
49.31%
$151.04M
Equity
Holdings
$151.04M
Investment
$124.05M
$60.68M
Profit -$1.67M
Realized
$33.69M
Unrealized
$26.99M
Dividends
$133,258.07
Goals
Avg. 48% completed goals
Yearly
Gain > 5% 2026
Yearly
Gain < 20% 2026
Today
Compared To Yesterday
Gain
-1.15%
Profit
-$1.67M
Win %
68%
This Week
Compared To Last Week
Gain
-0.42%
Profit
-$633,053.2
Win %
68%
This Month
Compared to last month
Gain
-5.55%
Profit
-$8.87M
Win %
68%
This Year
Compared to last year
Gain
-0.87%
Profit
-$1.32M
Win %
68%
ACRS Aclaris Therapeutics, Inc.
+2.04%
+$28,344.25 
ZLAB Zai Lab Ltd.
+1.9%
+$76,348.37 
VYNE Vyne Therapeutics Inc.
+1.73%
+$539.17 
GMAB Genmab A/S Sponsored ADR
+1%
+$148,557 
BMEA Biomea Fusion, Inc.
+0.84%
+$3,750 
ANL Adlai Nortye Ltd. ADR
+0.42%
+$35,912.57 
CABA Cabaletta Bio Inc.
+0.19%
+$6,393.26 
BEIGF BeiGene Ltd.
0%
$0 
VIR Vir Biotechnology Inc.
0%
$0 
SION Sionna Therapeutics Inc.
-8.36%
-$37,893.6 
HELP Cybin Inc.
-7.06%
-$202,379.76 
COGT Cogent Biosciences, Inc.
-3.44%
-$391,343.76 
RVMD Revolution Medicines Inc.
-2.31%
-$231,780.62 
TARA Protara Therapeutics Inc.
-2.3%
-$10,323.84 
CLDX Celldex Therapeutics Inc.
-2.1%
-$235,818.06 
PCVX Vaxcyte, Inc.
-2.02%
-$81,487.46 
AXSM Axsome Therapeutics, Inc.
-1.66%
-$191,401.8 
MPLT MapLight Therapeutics, Inc.
-1.54%
-$21,925.51 
TRVI Trevi Therapeutics Inc.
-1.45%
-$115,329.28 
IMVT Immunovant Inc.
-1.38%
-$108,351.36 
KNSA Kiniksa Pharmaceuticals International, plc
-1.16%
-$17,357.64 
SVRA Savara Inc.
-0.83%
-$43,985.7 
FTH Faeth Therapeutics, Inc.
-0.74%
-$3,685.5 
DFTX Definium Therapeutics, Inc.
-0.72%
-$52,285.91 
ORIC Oric Pharmaceuticals Inc.
-0.47%
-$24,364.62 
TNXP Tonix Pharmaceuticals Holding Corp
-0.44%
-$3,182.4 
ROIV Roivant Sciences Ltd
-0.35%
-$3,587.22 
CLYM Climb Biotherapeutics, Inc.
-0.3%
-$22,145.99 
UTHR United Therapeutics Corporation
-0.29%
-$10,435.19 
BOLD Boundless Bio, Inc.
-0.18%
-$276.78 
DRUG Bright Minds Biosciences Inc.
-0.11%
-$1,979.64 
URGN Urogen Pharma Ltd.
-0.09%
-$7,652.52 Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 362 | Longs Won 182/362 50% | Profit Factor 1.63 |
| Profitability | Shorts Won 0/0 0% | Standard Deviation $1.51M |
| Average Win $862,985.31 | Best Trade (Mar 30) $15.47M | Sharpe Ratio -42.11 |
| Average Loss -$535,487.66 | Worst Trade (Mar 30) -$5.19M | Z-Score -0.68 (50.58%) |
| Commissions $0 | Avg. Trade Length 6m 3d | Expectancy $167,612.01 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.04% | 0.71% | 9.66% |
| Consecutive Losing Trades | 282 | 254 | 226 | 197 | 169 | 141 | 113 | 85 | 56 | 28 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| ACRS Aclaris Therapeutics, Inc. | 257,675 | $966,281.61 | $1.42M | - | $453,507.64 | 46.93% | +2.037% |
| ANL Adlai Nortye Ltd. ADR | 552,501 | $4.33M | $8.48M | - | $4.15M | 95.81% | +0.425% |
| AXSM Axsome Therapeutics, Inc. | 53,916 | $12.5M | $11.36M | - | -$1.14M | -9.11% | -1.657% |
| BEIGF BeiGene Ltd. | 12,273 | $269,343.26 | $269,343.26 | - | - | - | 0.0 |
| BMEA Biomea Fusion, Inc. | 250,000 | $450,000 | $451,250 | - | $1,250 | 0.28% | +0.838% |
| BOLD Boundless Bio, Inc. | 55,356 | $138,390 | $154,720.02 | - | $16,330.02 | 11.8% | -0.179% |
| CABA Cabaletta Bio Inc. | 1.28M | $3.05M | $3.31M | - | $256,065.23 | 8.4% | +0.194% |
| CLDX Celldex Therapeutics Inc. | 287,583 | $9.31M | $10.97M | - | $1.66M | 17.88% | -2.104% |
| CLYM Climb Biotherapeutics, Inc. | 521,082 | $5.56M | $7.3M | - | $1.74M | 31.33% | -0.302% |
| COGT Cogent Biosciences, Inc. | 343,284 | $6.34M | $11M | - | $4.66M | 73.4% | -3.435% |
| DFTX Definium Therapeutics, Inc. | 188,282 | $3.56M | $7.23M | - | $3.67M | 103.19% | -0.718% |
| DRUG Bright Minds Biosciences Inc. | 30,456 | $2.01M | $1.87M | - | -$138,436.99 | -6.88% | -0.106% |
| FTH Faeth Therapeutics, Inc. | 14,175 | $354,375 | $494,282.25 | - | $139,907.25 | 39.48% | -0.74% |
| GMAB Genmab A/S Sponsored ADR | 430,600 | $11.44M | $15.02M | - | $3.58M | 31.25% | +0.999% |
| HELP Cybin Inc. | 204,424 | $1.23M | $2.66M | - | $1.43M | 116.45% | -7.061% |
| IMVT Immunovant Inc. | 208,368 | $3.96M | $7.74M | - | $3.78M | 95.37% | -1.381% |
| KNSA Kiniksa Pharmaceuticals International, plc | 18,867 | $1.21M | $1.48M | - | $272,816.47 | 22.61% | -1.16% |
| MPLT MapLight Therapeutics, Inc. | 125,432 | $2.55M | $1.4M | - | -$1.15M | -45.18% | -1.544% |
| ORIC Oric Pharmaceuticals Inc. | 406,077 | $3.9M | $5.21M | - | $1.31M | 33.62% | -0.466% |
| PCVX Vaxcyte, Inc. | 66,793 | $3.88M | $3.95M | - | $69,464.69 | 1.79% | -2.021% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
FAQ
Which stocks have generated the highest profits for George Song?
The largest contributions to the portfolio's profits come from the following stocks: Terns Pharmaceuticals, Inc - $24.22M, Cidara Therapeutics, Inc - $8.57M, Cogent Biosciences, Inc - $8.03M, NovoCure Ltd - $5.46M, and Definium Therapeutics, Inc - $4.59M. These positions have been the main drivers of growth and have significantly impacted the investor's overall performance.
Which stocks have generated the largest losses for this investor?
The largest losses in the portfolio are associated with the following stocks: Cytokinetics, Incorporated - $9.73M, Nkarta Inc - $5.58M, Marinus Pharmaceuticals Inc - $5.3M, Instil Bio, Inc - $5.19M, and Summit Therapeutics Inc - $4.31M. These positions have had the most negative impact on overall performance and highlight the weaker areas of the portfolio.
What dividends does George Song's portfolio generate?
The portfolio generates substantial dividend income, with a total of $133,258.07 earned over time. The largest contributors to dividend income include Pfizer Inc - $116,170.52, So-Young International Inc - $10,964.52, Regeneron Pharmaceuticals, Inc - $5,632.88, and Vyne Therapeutics Inc - $490.15. This indicates that dividends play a meaningful role in the investor's overall strategy.
How stable are George Song's monthly returns?
George Song's monthly returns look highly volatile. The portfolio shows large month-to-month swings, and the broader risk profile suggests that performance can change sharply over short periods. This kind of pattern may suit users who are comfortable with significant fluctuations, but it is less likely to appeal to those who prefer steadier and more predictable results.
Can George Song's strategy be considered aggressive or moderate?
George Song's strategy can be considered aggressive. The combination of high drawdowns, elevated volatility, and/or concentrated positions suggests a willingness to accept significant risk in pursuit of higher long-term returns. This approach is generally more suitable for users who are comfortable with large fluctuations in portfolio value.
Should beginners follow George Song's strategy?
George Song's strategy is unlikely to be suitable for beginners. The portfolio shows signs of high risk, significant volatility, or structural complexity, which can make it difficult to follow and potentially stressful for less experienced users. This type of approach is generally better suited to more advanced investors.
